![courtesy reuters courtesy reuters](https://i.tribune.com.pk/media/images/Annotation-2024-06-26-163524-matthew-perry1719402060-0/Annotation-2024-06-26-163524-matthew-perry1719402060-0.jpg)
Authorities are disclosing more information about Matthew Perry's final days following charges against five individuals related to his death.
The “Friends” star was discovered deceased in his Los Angeles home hot tub on October 28. The cause of death was later confirmed to be "acute effects of ketamine" due to drug and drowning-related factors.
This wasn’t Perry’s first encounter with adverse effects from ketamine. According to documents from the Department of Justice, reviewed by E! News on August 16, Perry had an "adverse medical reaction" to an at-home ketamine injection on October 12, just 16 days prior to his death.
Prosecutors claim that Dr. Salvador Plasencia administered "a large dose" of ketamine to the 54-year-old at the request of Perry’s live-in assistant Kenneth Iwamasa, who is also facing charges in this case, even though Perry had already received ketamine infusion therapy at a medical facility.
The DOJ reported that the at-home ketamine led to a "significant spike" in Perry’s systolic blood pressure, causing him to "freeze up" to the extent that he "could not speak or move."
Prosecutors assert that Plasencia advised Iwamasa with "something to the effect of: 'let’s not do that again'" after witnessing Perry’s reaction to the extra dosage. Despite this, the assistant continued to procure ketamine for home use in the days that followed.
Iwamasa has admitted guilt to one count of conspiracy to distribute ketamine causing death, according to authorities.
Plasencia is charged with one count of conspiracy to distribute ketamine, seven counts of distributing ketamine, and two counts of altering and falsifying documents related to the federal investigation. He has yet to publicly enter a plea.
COMMENTS
Comments are moderated and generally will be posted if they are on-topic and not abusive.
For more information, please see our Comments FAQ